Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital

Journal of Chemotherapy

Volumn 9, Issue 5, 1997, Pages 336-340

  Platsouka, E ^a   Zissis, N P ^b,c   Constantoulaki, S ^a   Paniara, O ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b Medical Department   (Greece)

^c NONE   (Greece)

Author keywords

Bacterial resistance; Beta lactamase; Piperacillin tazobactam

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEUS MIRABILIS; PSEUDOMONAS; STAPHYLOCOCCUS;

EID: 0030728861     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.5.336     Document Type: Article

References (17)

1. Bryan LE. General mechanisms of resistance to antibiotics. J Antimicrob Chemother 1988; 22(suppl A): 1-15.
2. Silver LL, Bostian KA. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob Agents Chemother 1993; 37: 377-383.
3. Gold HS, Moellering RC. Antimicrobial drug resistance. N Engl J Med 1996; 335: 1445-1453.
4. Murray BE. Problems and mechanisms of antimicrobial resistance. Infect Dis Clin N Am 1989; 3: 423-439.
5. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
6. Mandell GL. In vitro microbiology and pharmacokinetics of piperacillin. Clin Ther 1985; 7(Suppl B): 28-35.
7. Holmes B, Richards DM, Brogden RN, Heel RC. Pipcracillin, a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1984; 28: 375-425.
8. Livermore DM. Involution of beta-lactamase inhibitors. Intensive Care Med 1994; 20(Suppl 3): 10-13.
9. Baron EJ, Jones RN. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagn Microbiol Infect Dis 1995; 21: 141-151.
10. Chen HY, Bonfiglio G, Allen M, et al. Multicenter survey of the comparative in-vitro activity of piperacillin-tazobactam against bacteria from hospitalized patients in the British Isles. J Antimicrob Chemother 1993; 32: 247-266.
11. Verbist L, Verhaegen J, Wouters Ch, Vandenhoven G and multicenter study group. Comparative activity of piperacillin-tazobactam against 5625 isolates from hospitalized patients. J Antimicrob Chemother 1996; 37: 285-293.
12. O'Brien TF, Acar JF, Medeiros AA, Norton RA, Goldstein F, Kent RL. International comparison of prevalence of resistance to antibiotics. JAMA 1978; 239: 1518-1523.
13. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly and constitutively expressed Class I beta-lactamases. J Antimicrob Chemother 1990; 25: 199-208.
14. Moellering RC Jr. Importance of beta-lactamase inhibitors in overcoming bacterial resistance. Intect Dis Clin Pract 1995; 4(Suppl 1): 1-8.
15. Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother 1993; 31(Suppl A): 9-21.
16. The Greek Society for Microbiology. Antibiotic resistance among Gram negative bacilli in 19 Greek hospitals. J Hosp Infect 1989; 14: 177-181.
17. Legakis NJ, Tzouvelekis LS, Tsakris A, Legakis JN, Vatopoulos AC. On the incidence of antibiotic resistance among aerobic Gram-negative rods isolated in Greek hospitals. J Hosp Infect 1993; 24: 233-237.